Mental health experts have welcomed TGA approval of Servier's LATUDA (lurasidone HCl) for the treatment of schizophrenia in adolescents (aged 13-17 years) as “an important therapy” for young patients with what is a debilitating mental illness. …
New Stories
-
Seven candidates for MA Board vacancy
August 20, 2018 - - Latest News -
July PBAC: Immunotherapies, biosimilars and cystic fibrosis
August 20, 2018 - - Latest News -
Documents reveal more on confidentiality controversy
August 20, 2018 - - Latest News -
Evidence of a deliberate work-around
August 20, 2018 - - Comment -
PBAC Chair: Any change ultimately a matter for government
August 17, 2018 - - Latest News -
Government unhappy as big day arrives
August 17, 2018 - - Latest News -
Orphan designation change 'another barrier'
August 17, 2018 - - Latest News